Fonte: Cancer Chemotherapy and Pharmacology. Unidade: FMRP
Assuntos: INFLAMAÇÃO, FÁRMACOS, RECEPTORES
ABNT
WONG, Deysi Viviana T. et al. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemotherapy and Pharmacology, v. 84, n. 2, p. 287-298, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00280-019-03844-z. Acesso em: 18 ago. 2024.APA
Wong, D. V. T., Ribeiro Filho, H. V., Wanderley, C. W. S., Leite, C. A. V. G., Lima, J. B., Assef, A. N. B., et al. (2019). SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemotherapy and Pharmacology, 84( 2), 287-298. doi:10.1007/s00280-019-03844-zNLM
Wong DVT, Ribeiro Filho HV, Wanderley CWS, Leite CAVG, Lima JB, Assef ANB, Cajado AG, Batista GLP, González RH, Silva KO, Borges LPC, Alencar NMN de, Wilke DV, Cunha TM, Figueira ACM, Cunha F de Q, Lima Júnior RCP. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4 [Internet]. Cancer Chemotherapy and Pharmacology. 2019 ; 84( 2): 287-298.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1007/s00280-019-03844-zVancouver
Wong DVT, Ribeiro Filho HV, Wanderley CWS, Leite CAVG, Lima JB, Assef ANB, Cajado AG, Batista GLP, González RH, Silva KO, Borges LPC, Alencar NMN de, Wilke DV, Cunha TM, Figueira ACM, Cunha F de Q, Lima Júnior RCP. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4 [Internet]. Cancer Chemotherapy and Pharmacology. 2019 ; 84( 2): 287-298.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1007/s00280-019-03844-z